China's Innovent Biologics signs drug deal with Pfizer worth up to $10.5bn

China’s Innovent Biologics signs US$10.5b Pfizer deal for 12 cancer drug trials

The agreement covers eight early-stage trials from Innovent and four discovery programmes from global giant Pfizer.